Logo image of CGC

CANOPY GROWTH CORP (CGC) Stock Fundamental Analysis

NASDAQ:CGC - Nasdaq - CA1380357048 - Common Stock - Currency: USD

1.61  -0.06 (-3.59%)

After market: 1.61 0 (0%)

Fundamental Rating

2

Overall CGC gets a fundamental rating of 2 out of 10. We evaluated CGC against 194 industry peers in the Pharmaceuticals industry. The financial health of CGC is average, but there are quite some concerns on its profitability. CGC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CGC has reported negative net income.
CGC had a negative operating cash flow in the past year.
CGC had negative earnings in each of the past 5 years.
CGC had a negative operating cash flow in each of the past 5 years.
CGC Yearly Net Income VS EBIT VS OCF VS FCFCGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1B -2B -3B

1.2 Ratios

CGC has a Return On Assets (-40.34%) which is comparable to the rest of the industry.
CGC has a Return On Equity (-79.41%) which is in line with its industry peers.
Industry RankSector Rank
ROA -40.34%
ROE -79.41%
ROIC N/A
ROA(3y)-63.49%
ROA(5y)-47.06%
ROE(3y)-181.56%
ROE(5y)-123.98%
ROIC(3y)N/A
ROIC(5y)N/A
CGC Yearly ROA, ROE, ROICCGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

CGC has a Gross Margin of 30.40%. This is comparable to the rest of the industry: CGC outperforms 53.51% of its industry peers.
CGC's Gross Margin has improved in the last couple of years.
CGC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.93%
GM growth 5Y16.63%
CGC Yearly Profit, Operating, Gross MarginsCGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

4

2. Health

2.1 Basic Checks

CGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CGC has been reduced compared to 1 year ago.
Compared to 5 years ago, CGC has less shares outstanding
CGC has a better debt/assets ratio than last year.
CGC Yearly Shares OutstandingCGC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
CGC Yearly Total Debt VS Total AssetsCGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

Based on the Altman-Z score of -9.76, we must say that CGC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CGC (-9.76) is worse than 75.14% of its industry peers.
CGC has a Debt/Equity ratio of 0.79. This is a neutral value indicating CGC is somewhat dependend on debt financing.
CGC has a worse Debt to Equity ratio (0.79) than 70.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z -9.76
ROIC/WACCN/A
WACC9.75%
CGC Yearly LT Debt VS Equity VS FCFCGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B

2.3 Liquidity

CGC has a Current Ratio of 3.52. This indicates that CGC is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.52, CGC perfoms like the industry average, outperforming 54.59% of the companies in the same industry.
A Quick Ratio of 2.58 indicates that CGC has no problem at all paying its short term obligations.
CGC's Quick ratio of 2.58 is in line compared to the rest of the industry. CGC outperforms 49.73% of its industry peers.
Industry RankSector Rank
Current Ratio 3.52
Quick Ratio 2.58
CGC Yearly Current Assets VS Current LiabilitesCGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 74.54% over the past year.
CGC shows a decrease in Revenue. In the last year, the revenue decreased by -7.16%.
CGC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.60% yearly.
EPS 1Y (TTM)74.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.43%
Revenue 1Y (TTM)-7.16%
Revenue growth 3Y-18.39%
Revenue growth 5Y5.6%
Sales Q2Q%-2.44%

3.2 Future

The Earnings Per Share is expected to grow by 14.00% on average over the next years. This is quite good.
Based on estimates for the next years, CGC will show a small growth in Revenue. The Revenue will grow by 3.09% on average per year.
EPS Next Y59.83%
EPS Next 2Y36.74%
EPS Next 3Y20.3%
EPS Next 5Y14%
Revenue Next Year-17.13%
Revenue Next 2Y-7.94%
Revenue Next 3Y-0.68%
Revenue Next 5Y3.09%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CGC Yearly Revenue VS EstimatesCGC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
CGC Yearly EPS VS EstimatesCGC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGC Price Earnings VS Forward Price EarningsCGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGC Per share dataCGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

CGC's earnings are expected to grow with 20.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.74%
EPS Next 3Y20.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CGC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANOPY GROWTH CORP

NASDAQ:CGC (2/20/2025, 8:05:37 PM)

After market: 1.61 0 (0%)

1.61

-0.06 (-3.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-07 2025-02-07/bmo
Earnings (Next)05-30 2025-05-30/amc
Inst Owners8.79%
Inst Owner Change18.65%
Ins Owners0.06%
Ins Owner Change-5.03%
Market Cap279.14M
Analysts47.06
Price Target4.26 (164.6%)
Short Float %6.48%
Short Ratio1.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-164.26%
Min EPS beat(2)-231.12%
Max EPS beat(2)-97.39%
EPS beat(4)0
Avg EPS beat(4)-173.54%
Min EPS beat(4)-240.27%
Max EPS beat(4)-97.39%
EPS beat(8)1
Avg EPS beat(8)-220.15%
EPS beat(12)1
Avg EPS beat(12)-210.2%
EPS beat(16)4
Avg EPS beat(16)-163.89%
Revenue beat(2)1
Avg Revenue beat(2)4.18%
Min Revenue beat(2)-0.3%
Max Revenue beat(2)8.65%
Revenue beat(4)2
Avg Revenue beat(4)3.25%
Min Revenue beat(4)-8.11%
Max Revenue beat(4)12.74%
Revenue beat(8)4
Avg Revenue beat(8)2.69%
Revenue beat(12)5
Avg Revenue beat(12)-1.83%
Revenue beat(16)6
Avg Revenue beat(16)-2.69%
PT rev (1m)-1.49%
PT rev (3m)-26.52%
EPS NQ rev (1m)-3.58%
EPS NQ rev (3m)-89.34%
EPS NY rev (1m)-1.39%
EPS NY rev (3m)-39.43%
Revenue NQ rev (1m)3.39%
Revenue NQ rev (3m)-5.67%
Revenue NY rev (1m)-0.17%
Revenue NY rev (3m)-0.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.43
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.87
EV/EBITDA N/A
EPS(TTM)-3.66
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS1.12
BVpS2.4
TBVpS1.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.34%
ROE -79.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.4%
FCFM N/A
ROA(3y)-63.49%
ROA(5y)-47.06%
ROE(3y)-181.56%
ROE(5y)-123.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.93%
GM growth 5Y16.63%
F-Score6
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.12%
Cap/Sales 2.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.52
Quick Ratio 2.58
Altman-Z -9.76
F-Score6
WACC9.75%
ROIC/WACCN/A
Cap/Depr(3y)20.68%
Cap/Depr(5y)155.29%
Cap/Sales(3y)4.46%
Cap/Sales(5y)45.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.43%
EPS Next Y59.83%
EPS Next 2Y36.74%
EPS Next 3Y20.3%
EPS Next 5Y14%
Revenue 1Y (TTM)-7.16%
Revenue growth 3Y-18.39%
Revenue growth 5Y5.6%
Sales Q2Q%-2.44%
Revenue Next Year-17.13%
Revenue Next 2Y-7.94%
Revenue Next 3Y-0.68%
Revenue Next 5Y3.09%
EBIT growth 1Y64.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.93%
EBIT Next 3Y27.27%
EBIT Next 5Y16.78%
FCF growth 1Y70.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.6%
OCF growth 3YN/A
OCF growth 5YN/A